Ionis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Ionis Pharmaceuticals has a total shareholder equity of $662.5M and total debt of $1.8B, which brings its debt-to-equity ratio to 275.7%. Its total assets and total liabilities are $3.1B and $2.4B respectively.
Key information
275.7%
Debt to equity ratio
US$1.83b
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.49b |
| Equity | US$662.47m |
| Total liabilities | US$2.42b |
| Total assets | US$3.08b |
Recent financial health updates
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 01
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Recent updates
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Dec 23Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel
Dec 23Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 01Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Oct 23There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Financial Position Analysis
Short Term Liabilities: IONS's short term assets ($2.7B) exceed its short term liabilities ($304.6M).
Long Term Liabilities: IONS's short term assets ($2.7B) exceed its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: IONS has more cash than its total debt.
Reducing Debt: IONS's debt to equity ratio has increased from 43.8% to 275.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IONS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IONS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:55 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ionis Pharmaceuticals, Inc. is covered by 46 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |
| James Birchenough | Barclays |